{"schema_version":"secwatch.filing_event.v1","accession":"0001964738-25-000013","form_type":"8-K","ticker":"SOLV","cik":"0001964738","company_name":"Solventum Corp","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.667190+00:00","generated_at":"2026-05-26T02:35:07.688229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Solventum Q4 2024: GAAP EPS $0.17, adj. EPS $1.41, organic sales +2.3%","bullets":["GAAP diluted EPS $0.17; adjusted EPS $1.41; sales $2,074M (+1.9% reported, +2.3% organic).","GAAP operating income $136M (6.6% margin); adjusted $422M (20.4% margin); MedSurg and Dental drove growth.","Generated $219M cash from operations; free cash flow $92M.","Full-year 2024: sales $8,254M, GAAP EPS $2.76, adjusted EPS $6.70, free cash flow $805M.","Introduced FY 2025 guidance for organic sales growth, adjusted EPS, and free cash flow (specific figures not provided)."],"urls":{"canonical":"https://secwatch.observer/filing/0001964738-25-000013","json":"https://secwatch.observer/filing/0001964738-25-000013.json","markdown":"https://secwatch.observer/filing/0001964738-25-000013.md","text":"https://secwatch.observer/filing/0001964738-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964738/000196473825000013/0001964738-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964738/000196473825000013/solv-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:35:07.688229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}